AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida.
NCCN 2024 Annual Conference – Orlando World Center Marriott
| Poster – Friday, April 5, 2024 at 7:30am-8:30 am and 11:55am – 1:10 pm ET in the Exhibition Hall | |
| Title: | Rhenium (186Re) Obisbemeda (186RNL) in Leptomeningeal Metastases Phase 1 Dose Escalation Trial: Update of Initial Safety and Feasibility |
| Presenter: | Norman LaFrance, MD, ME, FACP, FACNP, FACNM (Chief Medical Officer of Plus Therapeutics) |
A copy of the poster presentation will be made available under the Presentations tab of the Investors section of the Company's website following the meeting at https://ir.plustherapeutics.com.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is ...
